Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3].

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Rizzari C.;
2023

Lettera in rivista
Antibodies, Bispecific; Child; Disease-Free Survival; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction
English
8-dic-2022
2023
37
1
222
225
none
Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/427802
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
Social impact